

Submitting Review Outcomes and Creating a Continuing Authorisation Request

Once an approved Immunoglobulin (Ig) Authorisation is nearing or has just exceeded its expiry date, BloodSTAR will notify Medical Officers involved with the authorisation and prompt them to submit review outcomes and will provide the option to submit a Continuing Authorisation Request.

Recording Review Outcomes

There are two ways of recording patient review outcomes.

1. Option one: click on the link in your emailed notification and you will be automatically directed to the relevant BloodSTAR message in the *BloodSTAR Messages* tab. Within that relevant message, click the link *Record Review Outcomes* at the bottom.

Review Reminder - DOE, John

11-Jun-2016

This patient is due for clinical review in accordance with the criteria for access to immunoglobulin products supplied under the national blood arrangements.

To access continued treatment for this patient you must complete a clinical review and submit a Continuing Authorisation Request **before 25-Jul-2016**. Failure to request continuing authorisation will cease the patient's access to treatment and you will be required to submit a new Initial Authorisation Request if continuing treatment is required.

For further information please contact the Authoriser on 02 62123456789

[Record Review Outcomes](#)

Option two: once you are logged in as a Medical Officer select the *Pending Reviews* tab. This will display all authorisations that require review in the next 8 weeks or those that have expired in the last 8 weeks. Locate the patient you want to record a review for and click *Record Review*.

BLOODSTAR

Home Patients Authorisation Requests Treatment BloodSTAR Messages

My Authorised Patients **Pending Reviews** Requests

Patient	Date of Birth	Treating Facility	Patient ID	Medical Condition	Review Due Date	
CITIZEN Simon	01-Jan-1980	The Royal Adelaide Hospital		Primary immunodeficiency diseases (PID) with antibody deficiency	29-Jun-2016	Record Review

10 items per page 1 - 1 of 1 items

2. On the *Review Outcome Form*, confirm that all patient details are correct and, if necessary, change or update them by selecting *Edit Patient Details*.
3. Scroll down, enter the review date and nominate the Reviewing Medical Officer

- Under *Review Criteria*, select all applicable options for the *Qualifying Criteria* according to your patient's condition and fill in all relevant *Supporting Evidence* details. These options are dependent on the original diagnosis and, if selected, will create fields for you to enter more information about the patient.
- In *Review Outcome*, select the overall review outcome from the available options:

Review Outcome

Review Outcome * **A** **Request Continuing Treatment**
These review outcomes provide supporting information for the assessment of an additional authorisation period.

B **Review Only**
Record a review without requesting continuing treatment. Access to therapy will continue unchanged to the authorisation end date.

C **Cease Treatment**
End the current authorisation now because Ig therapy is no longer required, or is being requested under a different indication.

- Option to request continuing treatment for the current Ig Authorisation.
- Record a review/change on the authorisation without requesting continuing treatment.
- If you elect to end the current authorisation you will be prompted to enter a Cessation Date if it is to end immediately. Enter the date if earlier than the current authorisation end date and click *Submit*.

Creating a Continuing Authorisation Request

- If you selected *Request Continuing Treatment* under *Review Outcomes*, a section labelled *Continuing Authorisation Request* will appear. Enter your patient's weight and the dosing regimen you would like to submit for authorisation.

Continuing Authorisation Request

Patient Weight * kg Use Ideal Body Weight Adjusted Dosing

Maintenance Dose

Subcutaneous administration of immunoglobulin can be considered as an alternative to IVIg. A suggested dose is 0.1 g/kg lean body mass every week, modified to achieve an IgG trough level of at least the lower limit of the age-specific serum IgG reference range.


The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.



Refer to the current product information sheet for further information.


- Once these details are entered, click the checkbox next to the *Terms and Conditions* and click *Submit*.

Submitting a Continuing Authorisation Request when there is one or more planned doses remaining in the previous authorisation

1. The system will prepopulate the date required to be the same as the next planned date and display a message saying “Date required matches the next planned date. There is no treatment gap.”





Date Required * 28-Apr-2023  Approximate End Date 

 Date required matches the next planned date. There is no treatment gap.

When requesting a Continuing Authorisation Request for the same dose type (IVIg to IVIg or SCIg to SCIg) and the date required is changed, creating a *treatment gap*.

1. The system will display a pop-up message advising the date entered creates a treatment gap the system will suggest an alternative treatment date to avoid a gap in treatment. The suggested date is based on the frequency selected in the new request.



Requested Date Confirmation 

Approval of this continuing authorisation request will override the current authorisation and cancel any undispensed doses.

The **Date Required** selected falls outside the chosen frequency. Proceeding may cause a gap in the patient's treatment plan since their last treatment was on **31-Mar-2023**. Based on the frequency selected, the next expected dose would be **28-Apr-2023**.

To prevent a gap in the treatment plan, should **28-Apr-2023** be the Date Required?

If you select “No – keep the date entered”, the date you entered (e.g. 20 May 2023) will become the date of the first approved dose for this Continuing Authorisation Request. This may cause a gap in the treatment as specified in the pop-up

If you select “Yes – change date to [Insert date]”, the date suggested by the system (e.g. 28 April 2023, in the example above) will be the date of the first dose for this Continuing Authorisation Request. This function is designed to reduce the number of unintentional gaps in a patient’s treatment plan.